Delcath Systems, INC.: management transactions · United States · SEC (Form 4)

About Delcath Systems, INC.

Delcath Systems, Inc. is a U.S.-based oncology-focused healthcare company listed on the Nasdaq Capital Market under the ticker DCTH, in the United States. Founded in 1988, the company was built around a highly specialized mission: developing liver-directed drug delivery systems designed to deliver high-dose chemotherapy to the liver while reducing systemic exposure. Its operating headquarters are in Queensbury, New York, giving Delcath the profile of a U.S. healthcare small cap with a strong clinical and regulatory overlay. ([investors.delcath.com](https://investors.delcath.com/ir-resources/faqs?utm_source=openai)) Delcath’s business is centered on two commercial platforms. In the U.S., the flagship product is HEPZATO KIT, a drug/device combination product used in the treatment of primary and metastatic liver cancers, especially where disease is liver-dominant. In Europe, the company markets CHEMOSAT, the device-based version of its hepatic delivery system, which is used at specialized medical centers for liver cancer treatment. This creates a business model that combines specialty pharma, medical devices, and clinical center activation and support. ([delcath.com](https://delcath.com/about-us/?utm_source=openai)) From a competitive standpoint, Delcath occupies a narrow but differentiated niche. It is not a broad diversified pharma group; instead, it is a focused interventional oncology player addressing a specific clinical need: regional hepatic chemotherapy delivery. That focus can be an advantage because it creates clear therapeutic positioning and a potentially defensible technology platform, but it also means the business is highly dependent on physician adoption, reimbursement, regulatory execution, and the pace of center activation. The FDA approval of HEPZATO and the establishment of a product-specific reimbursement code are important commercial milestones that support adoption and monetization. ([sec.gov](https://www.sec.gov/Archives/edgar/data/872912/000162828026022951/dcth202510kforproxy.pdf?utm_source=openai)) Recent developments point to meaningful momentum. In 2025, Delcath reported strong revenue growth driven primarily by HEPZATO KIT, along with improving gross margins and an expanding treatment-center footprint. The company also advanced its clinical franchise: CHOPIN data were published in The Lancet Oncology in 2026, adding external validation to the platform’s clinical rationale. For investors, Delcath remains a specialized U.S. Nasdaq healthcare name with high operating leverage, where the key watch items are reimbursement durability, commercial uptake, clinical expansion, and continued execution in the U.S. and Europe. ([investors.delcath.com](https://investors.delcath.com/news-releases/news-release-details/delcath-systems-reports-fourth-quarter-and-full-year-2025?utm_source=openai))